Bavarian Nordic in talks for potential prostate cancer vaccine

Bavarian Nordic, whose main product is the Imvamune, a vaccine for small pox, is currently in talks with major Pharma companies about partnering to produce a vaccine for prostate cancer according to Reuters.

The company stated:
"Bavarian Nordic is actively pursuing its strategy for partnering with a global pharmaceutical company for the Phase III development and commercialisation of Prostvac, which has attracted significant interest. Bavarian Nordic is currently in advanced discussions with a number of companies, including some of the largest, with due diligence ongoing."

The company was granted fast track status, and could have patients in clinical trails as soon as 2011.

Bavarian Nordic will be speaking at Vaccines Business Congress this March 2-4, 2011, in Baltimore. They will be presenting with the National Cancer Institute. To find out more about their presentation, and the full Vaccines Business Congress agenda, download the brochure here.

Share this article with your social network, just click below to share now!

Share |